Early prediction of clinical benefit of treating ovarian cancer using quantitative CT image feature analysis

Acta Radiologica

Volumn 57, Issue 9, 2016, Pages 1149-1155

  Qiu, Yuchen ^a   Tan, Maxine ^a   McMeekin, Scott ^b   Thai, Theresa ^b   Ding, Kai ^b   Moore, Kathleen ^b   Liu, Hong ^a   Zheng, Bin ^a  

^a University of Oklahoma   (United States)

^b UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

adults; clinical trial of treating ovarian cancer; Computed tomography (CT); computer aided detection; genital; prediction of 6 month progression free survival; progress free survival (PFS); quantitative CT image feature analysis; reproductive; treatment effects

Indexed keywords

CHEMOTHERAPY; COMPUTER AIDED ANALYSIS; DECISION TREES; DISEASES; FORECASTING; IMAGE ANALYSIS; IMAGE SEGMENTATION; MEDICAL APPLICATIONS; TUMORS;

ADULTS; COMPUTER AIDED DETECTION; GENITAL; OVARIAN CANCERS; PROGRESS-FREE SURVIVAL (PFS); PROGRESSION FREE SURVIVAL; QUANTITATIVE CT; REPRODUCTIVE; TREATMENT EFFECTS;

COMPUTERIZED TOMOGRAPHY;

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CABOZANTINIB; COMBRETASTATIN A4 PHOSPHATE; CYTOTOXIC AGENT; DOXORUBICIN; IOPAMIDOL; PACLITAXEL; PAZOPANIB; PELAREOREP;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLASSIFIER; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG RESPONSE; FEMALE; HUMAN; IMAGE ANALYSIS; OVARY CANCER; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; RETROSPECTIVE STUDY; TUMOR VOLUME; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC IMAGING; DISEASE FREE SURVIVAL; MIDDLE AGED; OVARIAN NEOPLASMS; PROCEDURES; VERY ELDERLY; X-RAY COMPUTED TOMOGRAPHY;

AGED; AGED, 80 AND OVER; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; RADIOGRAPHIC IMAGE INTERPRETATION, COMPUTER-ASSISTED; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84986005695     PISSN: 02841851     EISSN: 16000455     Source Type: Journal    
DOI: 10.1177/0284185115620947     Document Type: Article

References (26)

1. Siegel RL, Miller KD, Jemal A,. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
2. Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008; 8: 11-23.
3. Goetsch CM,. Genetic tumor profiling and genetically targeted cancer therapy. Semin Oncol Nurs 2011; 27: 34-44.
4. Sequist LV, Heist RS, Shaw AT, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 2011; 22: 2616-2624.
5. Tempany CMC, Zou KH, Silverman SG, et al. Staging of advanced ovarian cancer: Comparison of imaging modalities-Report from the Radiological Diagnostic Oncology Group. Radiology 2000; 215: 761-767.
6. Gu P, Pan LL, Wu SQ, et al. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma A systematic review and meta-analysis. Eur J Radiol 2009; 71: 164-174.
7. Petitjean A, Achatz MIW, Borresen-Dale AL, et al. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26: 2157-2165.
8. Vockley JG, Creighton CJ, Nichol R, et al. Integrated genomic analyses of ovarian carcinoma. Nature 2012; 490: 292-292.
9. Gupta D, Lis CG,. Role of CA125 in predicting ovarian cancer survival-a review of the epidemiological literature. J Ovarian Res 2009; 2: 13-13.
10. Patsner B, Orr JW Jr, Mann WJ Jr, et al. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease? Gynecol Oncol 1990; 38: 373-376.
11. Rustin GJS, van der Burg MEL, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer: a randomised trial. Lancet 2010; 376: 1155-1163.
12. Kyriazi S, Kaye SB, deSouza NM,. Imaging ovarian cancer and peritoneal metastases-current and emerging techniques. Nat Rev Clin Oncol 2010; 7: 381-393.
13. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
14. Andreopoulou E, Andreopoulos D, Adamidis K, et al. Tumor volumetry as predictive and prognostic factor in the management of ovarian cancer. Anticancer Res 2002; 22: 1903-1908.
15. Sharma MR, Maitland ML, Ratain MJ,. RECIST: No longer the sharpest tool in the oncology clinical trials toolbox point. Cancer Res 2012; 72: 5145-5149.
16. Fallowfield LJ, Fleissig A,. The value of progression-free survival to patients with advanced-stage cancer. Nat Rev Clin Oncol 2012; 9: 41-47.
17. Zheng B, Chang YH, Gur D,. Computerized detection of masses in digitized mammograms using single-image segmentation and a multilayer toppgraphic feature analysis. Acad Radiol 1995; 2: 959-966.
18. Cha K, Hadjiiski L, Chan HP, et al. CT urography: segmentation of urinary bladder using CLASS with local contour refinement. Phys Med Biol 2014; 59: 2767-2785.
19. Zheng B, Shah R, Wallace L, et al. Computer-aided detection in mammography: An assessment of performance on current and prior images. Acad Radiol 2002; 9: 1245-1250.
20. Lederman D, Zheng B, Wang XW, et al. Improving Breast Cancer Risk Stratification Using Resonance-Frequency Electrical Impedance Spectroscopy Through Fusion of Multiple Classifiers. Ann Biomed Eng 2011; 39: 931-945.
21. Wang XW, Li SB, Liu H, et al. Automated identification of analyzable metaphase chromosomes depicted on microscopic digital images. J Biomed Inform 2008; 41: 264-271.
22. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res 2009; 15: 7412-7420.
23. Hoos A, Eggermont AMM, Janetzki S, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010; 102: 1388-1397.
24. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A gynecologic oncology group study. J Clin Oncol 2007; 25: 5165-5171.
25. Schrader J, Gordon-Walker TT, Aucott RL, et al. Matrix Stiffness Modulates Proliferation, Chemotherapeutic Response, and Dormancy in Hepatocellular Carcinoma Cells. Hepatology 2011; 53: 1192-1205.
26. Slaughter KN, Thai T, Penaroza S, et al. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer. Gynecol Oncol 2014; 133: 11-15.